Disorder, Study, Treatment, Resistant, Enrollment, Phase, compulsive, initiates, obsessive, TO2061, Transcept


JUS†ICE




Image by Caesar Sebastian

L.A. Weekly - L.A Detour

Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and ...

Read more on News-Medical-Net




















Similar posts to:

Disorder:

A House in Gross Disorder: Sex, Law, and the 2nd Earl of Castlehaven ...
My husband is amazing in bed, I have a thyroid disorder and do not crave sex! How do I increase my drive? ...
Study:

Women Want Internet Over Sex – Study ...
Scent in the Islamic Garden: A Study of Deccani Urdu Literary Sources ...
A Study of Sex workers in Sri Lanka; An Example of Using Public Health Methodologies in Behavioral Research. ...
Public Health Methodologies in Behavioral Research Among Vulnerable Populations in Developing Countries: A STUDY OF SEX WORKERS IN SRI LANKA ...
Treatment:

Color Me Sexy Colorset Moisturizing Treatement Mas Sexy Hair 8.5 oz Treatment For Unisex ...
Fu*kin For Benefits? NYC Female School Safety Agents Have Sex With Bosses And Receive Better Treatment ...
Complete Vaginismus Treatment Kits ...
Resistant:

Enrollment:

Phase:

compulsive:

initiates:

obsessive:

TO2061:

Transcept: